Adult Immunization

Anaphylaxis

Food Allergies

Seasonal Allergies

Allergy

Atrial Fibrillation

Heart Failure

Hypertension

Lipid disorders

Cardiology

Clinical Technology

Atopic Dermatitis

Psoriasis

Rosacea

Dermatology

Adrenal Disorders

Diabetes

Thyroid Disorders 

Endocrinology 

C Difficile Infection

Celiac disease

GERD

Inflammatory Bowel Disease

Irritable Bowel Syndrome 

Gastroenterology

Hepatitis

MASLD/MASH

Hepatology

Coronavirus

HIV AIDS

Hepatitis C

Influenza

Pneumonia

Sexually transmitted infections

Infectious Disease

Chronic Kidney Disease

Nephrology

Alzheimer Disease/Dementia

Cerebrovascular Diseases

Epilepsy

Headache

Mental Health

Migraine

Parkinson Disease

Sleep Disorders

Neurology

Obesity Medicine

Fibromyalgia

Pain Management

Pediatric Immunization

Pediatrics

ADHD

Anxiety

Depression

Eating Disorders

PTSD

Panic Disorder  

Psychosis

Substance-related Disorders

Psychiatry 

Asthma

COPD

Cystic Fibrosis

Interstitial lung disease

Pulmonary hypertension

Pulmonology

Gout

Lupus

Osteoarthritis

Psoriatic arthritis

Rheumatoid Arthritis

Rheumatology

Breast Cancer

Cervical Cancer

Colorectal Cancer

Lung Cancer

Melanoma

Prostate Cancer

Renal Cancer

Skin cancer

Screening

Menopause

Osteoporosis

Pregnancy and Birth

Women's Health

News

All News

Editorial Podcasts

Practice Management

Video Interviews

Media

Around the Practice

Between the Lines

ConsultantLive

Frontline Insights

Institutional Insights

Primary View

Provider Toolkits

Screening Series

Conferences

Conference Coverage

Conference Listing

Product Theater Recaps

Resources

Interactive Posters

Product Profile

Publications

Subscribe

CE/CME

Patient Care Online offers clinical news and resources for primary care clinicians, focusing on disease states, guidelines, and trends to improve care.

About Us

Advertise

Contact Us

Editorial Board

Terms and Conditions

Privacy

Do Not Sell My Information

Patient Care Online – Primary Care News and Clinical Resources

Facebook

LinkedIn

Clinical Focus

Allergy & Immunology

Endocrinology

Men’s Health

Psychiatry

Women’s Health

Business Focus

Billing and Collections

Career Planning

Coding and Documentation

Concierge Medicine

Cybersecurity

EHRs

Investing

Patient Relations

Personal Finance

Remote Patient Monitoring

Staffing

Technology

Telehealth

Value-based Care

Spotlight

VMS and Menopause

Atopic Dermatitis Provider Toolkit

Adult Immunization Provider Toolkit

Dermatology Hot Topics

1rem

Authors

Hidradenitis suppurativa is a chronic acneiform infection of the cutaneous apocrine glands.

Infection of the Cutaneous Apocrine Glands

A 68-year-old man presented with two growths on his chest, which he said had been slowly expanding over the past 2 years. They were occasionally tender and had bled with minimal trauma.

Can you identify the 2 slowly expanding growths on the chest of this 68-year-old man?

Clinical Topics

Pearly Pink Chest Lesions 

The mother of a 10-year-old boy brings him in for evaluation of his moles (which are all benign). During the visit, the mother asks about the lesions on the first 2 knuckles of his right hand; she initially noticed them several months earlier. The boy is otherwise healthy.

White Knuckles

Lifestyle Interventions for Treatment and Remission of Prediabetes and T2D: There's a Guideline for That? 

Yes, there is a clinical practice guideline for that, recently published by the American College of Lifestyle Medicine (ACLM). 

Lifestyle interventions for the treatment and remission of type two diabetes and prediabetes in adults

according to authors, that  places lifestyle modification at the center of care for adults with 

In an interview with Patient Care, guideline lead author Richard Rosenfeld, MD, MPH, MBA, talked about the timing of the publication of the ACLM recommendations. Although the release in the A

¹ was the next step in an iterative development process, the publication is in ideal synch with the state of American's health, Rosenfeld stressed. "Over half the US population has either prediabetes, about 38%, or type 2 diabetes, about 14.5%" and there is a proportion who "don't even know they have it." Add the obesity epidemic into the equation, and "the timing really just seemed right to do this." 

Rosenfeld adds that the evidence based to support the essential role of durable lifestyle change in reducing the risk for type 2 diabetes (T2D) and even in reversing the disease, is growing rapidly. He discusses the development of the ACLM guideline in the short video above and the goal of remission of T2D. 

For an at-a-glance preview of the 14 lifestyle interventions recommended in the guideline, see 

Guideline Topline: 14 Key Lifestyle Interventions to Treat, Prevent Type 2 Diabetes

Richard Rosenfeld, MD, MPH, MBA, is the distinguished professor of otolaryngology, SUNY Downstate Health Sciences University and senior advisor for quality and guidelines for the American Academy of Otolaryngology – Head and Neck Surgery. Rosenfeld is board certified in otolaryngology – head and neck surgery and in lifestyle medicine. 

The American College of Lifestyle Medicine recently published "that guideline," and lead author Richard Rosenfeld, MD, MPH, MBA, says the timing was right. 

Jonathan Bonnet, MD, MPH, is a coauthor of a recent 

 warns of the potential challenges associated with GLP-1 receptor agonist therapy for management of obesity. As use of the potent medications has grown increasingly widespread, so has documentation of adverse effects during treatment, including protein and other nutrient deficiencies and loss of lean mass and bone mass.  

“Nutritional Priorities to Support GLP-1 Therapy for Obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society,”

 doesn't just warn of the potential issues. It provides a comprehensive guide to patient assessment and the use of structured evidence-based nutritional and lifestyle strategies to address a wide range of challenges around GLP-1 treatment of obesity. 

 sat down with Bonnet for a question and answer session and the transcript follows here. Bonnet is program director of medical weight loss at the  Clinical Resource Hub Weight Management Center, Palo Alto VA, and holds an affiliate appointment at Stanford University. He is board-certified in family, sports, obesity, and lifestyle medicine. 

 The Q&A transcript has been lightly edited for style and clarity. 

Patient Care: How did the concept for the joint advisory on nutritional priorities to support GLP-1 medication use in obesity come about?

 I think by now most people have heard about GLP-1s—they’re being used pretty widely. We’re still figuring out how to use them in the best possible way so patients get great results without creating new problems. Any time there’s a new drug, there’s an art to it. It’s not just, “Here, take this pill and see what happens.” You need support and resources in place.

When you give a drug to thousands—or millions—of people, you learn a lot fast: the side effects, how it’s affecting people’s daily lives, what behaviors they are or aren’t changing. The question we asked was: how can we best support patients nutritionally—maybe even on the exercise side? What new challenges will they run into? And how do we make sure the benefits of the drug are backed up with lifestyle habits that help them succeed for the long haul?

PC: Beyond nutritional deficiencies, what other challenges does the advisory highlight?

 First off, not everyone responds the same. Some people do great, some not at all, and a lot fall somewhere in between. Then there’s the side effects—GI issues are a big one. Nausea tops the list. Eating small, frequent meals and not skipping meals can help. For constipation, we push high-fiber, high-water foods. Reflux? Maybe it’s spicy foods, eating too late, or lying down right after meals—you can often fix that with simple changes.

The other big thing is that because these meds turn down appetite so much, people sometimes don’t get enough key nutrients—especially protein and fiber. Low protein puts them at risk for muscle loss, which is why we also talk about resistance training. And of course, there are the bigger-picture concerns: cost, and the fact that we still don’t have 10-year safety data.

PC: The advisory recommends a thorough baseline nutritional assessment before prescribing GLP-1s. Is that being overlooked, and what’s most often missed?

 In obesity medicine, I’ve got more time to dig deep. In primary care, I know time is tight. But even then, there are a few non-negotiables. You’ve got to know the patient’s weight history—when they lost, when they gained, what was going on in their life. Did they start a new medication? Did something major happen?

You also need to know if they’ve ever had an eating disorder. A lot of people have tried every diet under the sun, and it’s not hard to end up with disordered eating along the way. And you need to get to the root cause. Is it poor sleep? Too much ultra-processed food? No physical activity? Medications? Depression? Anxiety? If you don’t figure that out, you’re just suppressing appetite without fixing the actual problem.

Plus, there are contraindications and a few drug interactions you don’t want to miss.

PC: The advisory stresses combining nutritional, behavioral, and lifestyle strategies with medication. How should primary care approach this?

 You don’t have to do it all in one visit, and you don’t have to do it alone. Use your team—dietitians, behavioral psychologists, PTs, health coaches.

Like it or not, GLP-1s are here to stay. They’re probably going to be the biggest-selling drugs of all time—likely passing statins—unless something really unusual happens. And obesity? I’d argue it’s literally and figuratively our biggest healthcare challenge. Look at all the comorbidities: high blood pressure, high cholesterol, prediabetes, diabetes, sleep apnea, fatty liver, joint pain, heart disease, some cancers. If you treat obesity well, you move the needle on all of them.

Primary care docs already manage diabetes, and these drugs are part of that, so they’re not foreign territory. Sure, send the tough cases to an obesity specialist, but not every patient with obesity needs a referral—just like you don’t send everyone with arthritis straight to an orthopedist.

PC: Where is research most needed for integrating nutrition and medication in obesity care?

 The big question: Are these forever drugs? Right now, the best data says… probably. There are ideas about weaning people off—alternate dosing, combining low doses of different meds, using intensive nutrition programs—but no rock-solid evidence yet that you can get people off GLP-1s without significant weight regain.

I’d also love more clarity on nutrient targets, especially protein. We suggested in our paper: 0.8 g/kg/day if you don’t adjust for body weight, or 1.2–1.6 g/kg of adjusted body weight per day if you do. That’s a big range. Same with other nutrients—we need to know what’s optimal during weight loss. And down the line, what does the “off-ramp” diet look like if you’re trying to transition someone off the drug without undoing all the progress?

PC: You’ve worked on guidelines for using lifestyle medicine in prediabetes and type 2 diabetes. What are the core principles of this approach? 

 The American College of Lifestyle Medicine has six pillars. I like the easy version: what you do with your feet, your fork, and your fingers; how you manage stress and sleep; and whether you have loving, meaningful relationships.

Translated: physical activity, healthy nutrition, avoiding harmful substances, restorative sleep, stress management, and social connection. There’s mountains of data showing these help prevent disease—and when done right, they can treat or even reverse some conditions.

They’re inexpensive, accessible, and work for the long run. That doesn’t mean ditch the meds. It’s lifestyle first, with medications as needed, so people can not just lose weight but keep it off and stay healthy for life.

PC: Would you leave us with 3 take-home suggestions for primary care from the advisory?

Take obesity as seriously as other chronic conditions.

 If someone walked in with a BP of 190/110, you wouldn’t just wave goodbye. Yet we do that with high BMI all the time. Address it respectfully, without judgment, and give patients something actionable.

Lead with lifestyle, use meds when appropriate.

 I’m a lifestyle-first guy. We often skip straight to pharmacology because it’s easier than walking through a lifestyle prescription—but lifestyle benefits everything you treat, not just weight.

Obesity medicine expert Bonnet answers questions about the downsides of GLP-1 therapy for obesity management and how lifestyle medicine interventions will help. 

Arash Asgarian Nahavandi, MD

Articles

Latest Updated Articles